Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06186622 · ClinicalTrials.gov registry record · Phase 1
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT06186622 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 50 participants.
The verdict
NCT06186622, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine effect of orforglipron capsule formulation on the amount of digoxin, rosuvastatin, acetaminophen, midazolam, and simvastatin (each given alone and together with orforglipron) that enters the bloodstream and how long it takes the body to eliminate them when administered orally in healthy overweight and obese participants. In addition, the effect of the orforglipron tablet on the amount of simvastatin that enters the bloodstream and how long it takes the body to eliminate it will be evaluated. The study will also assess the effect of sodium bicarbonate when administered alone with simvastatin versus orforglipron capsule containing sodium bicarbonate administered with simvastatin. The safety and tolerability of orforglipron and information about any side effects experienced will be collected. Study will be conducted in two parts, with part 1 and 2 lasting up to approximately 23 and 24 weeks each, including the screening period.
Interventions
- DRUG Acetaminophen
- DRUG Orforglipron
- DRUG Rosuvastatin
- DRUG Simvastatin
- DRUG Digoxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-01-02 |
| Est. Completion | 2024-07-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06186622
The ClinicalTrials.gov registry entry for NCT06186622 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Acetaminophen is the first listed.
NCT06186622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06186622 about?
NCT06186622 is a clinical study titled "A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants". The main purpose of this study is to determine effect of orforglipron capsule formulation on the amount of digoxin, rosuvastatin, acetaminophen, midazolam, and simvastatin (each given alone and together with orforglipron) that enters the bloodstream and how long it takes the body to eliminate them w...
What is the current status of trial NCT06186622?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2024-01-02. Estimated completion is 2024-07-10.
What interventions are being tested in trial NCT06186622?
The interventions under investigation include: Acetaminophen (DRUG), Orforglipron (DRUG), Rosuvastatin (DRUG), Simvastatin (DRUG), Digoxin (DRUG).
Who is sponsoring clinical trial NCT06186622?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.